Avastin has been used for several years as a treatment for Macular Degeneration. While not an FDA approved treatment, Avastin was shown to not only halt the progression of wet macular degeneration, but also reverse the affects of the eye disease in some cases. A new study has now shown that treatment of macular degeneration with Avastin and Lucentis is different.
The preliminary data reported at the American Society of Retina Specialists indicate that there is a difference between Avastin (bevacizumab) and Lucentis (ranibizumab) as a treatment for Macular Degeneration. The difference is in the short-term biological effect and in the durability of activity. This leads to differences in remission intervals in patients treated with Avastin or Lucentis for wet macular degeneration.
In a retrospective study of 52 patients that had been treated with Lucentis and 68 patients that had been treated for macular degeneration with Avastin, it was shown that the mean remission times were 6.6 months for Avastin and 3.8 months for Lucentis.
Using optical coherence tomography (OCT) to conduct qualitative analysis, the recurrence of choroidal neovascular activity in wet macular degeneration was found after treatments of either Avastin or Lucentis.
Dr. Chang and his colleagues who completed the study indicated that the advantage of Lucentis as a treatment for macular degeneration was in its short-term biological effect. The advantage of Avastin as a treatment for macular degeneration is in its durability of activity.